At a glance
ClinicalIndex Comparison RecordPhase 2Active· 1 enrolled
Drug / intervention
Somatropindrug
Likely dose
Somatropin 50 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Growth Hormone in a Patient With a Dominant-Negative GHR Mutation
In Brief
A Phase 2 clinical trial evaluating Somatropin for Growth Disorders. Active but no longer recruiting, targeting 1 participant across 1 site.
Detailed Summary
This is a prospective interventional study designed for a single patient with a dominant-negative mutation in the growth hormone receptor gene (GHR) which results in increased levels of growth hormone binding protein (GHBP). The patient will receive escalating doses of growth hormone titrated to achieve an insulin like growth factor-1 level above the mean and then growth response to therapy will be monitored.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Disorders
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
202320242025202620272028
First PostedMay 2022
Enrollment StartAug 2022
Primary CompletionSep 2023
TodayJul 2026
Study CompletionSep 2028
First PostedMay 19, 2022
Enrollment StartAug 26, 2022
Primary CompletionSep 1, 2023
Study CompletionSep 1, 2028
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 4.1 years ago
Interventions
Somatropindrug
Daily growth hormone at a starting dose of 50 mcg/kg/day and escalating